Analytica (Subject to Deed of Company Arrangement)
Analytica's lead product is the PeriCoach® System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles during pregnancy, childbirth and menopause.
PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal.
This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.
PeriCoach has Australia regulatory clearance in Australia, CE mark and FDA 510(k) clearance. The US market for incontinence pads is $5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. PeriCoach is available from the PeriCoach.com website.
PeriCoach also has TGA clearance for the treatment of Pelvic Organ Prolapse, a condition which affects 1 in 6 women during their lifetimes.
Investment Information
Analytica Limited (ABN 12 006 464 866) is a Brisbane-based public company listed on the Australian Stock Exchange (ASX Code: ALT). For more information, see About Us and ASX Releases.